AstraZeneca AB: clinical-trial pipeline
AstraZeneca AB is the sponsor of 3,526 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 525 are not yet finished and 17 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials525
Phase 2/3 and 3830
Countries92
New in 90 days17
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 978 |
| Phase 1 | 968 |
| Phase 3 | 812 |
| Phase 2 | 477 |
| Phase 4 | 192 |
| Phase 1/2 | 70 |
| Phase 2/3 | 18 |
| Early phase 1 | 11 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 2,709 |
| Recruiting | 242 |
| Active, not recruiting | 238 |
| Terminated | 223 |
| Withdrawn or not authorised | 59 |
| Not yet recruiting | 45 |
| Suspended or halted | 7 |
| Unknown | 3 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 960 |
| Respiratory | 656 |
| Metabolic and endocrine (diabetes, obesity) | 442 |
| Cardiovascular | 406 |
| Gastroenterology and liver | 256 |
| Nephrology and urology | 221 |
| Psychiatry and mental health | 175 |
| Immunology and rheumatology | 151 |
| Rare and genetic diseases | 99 |
| Women's health and obstetrics | 97 |
| Infectious disease and vaccines | 95 |
| Neurology | 77 |
Countries
| Country | Trials |
|---|---|
| United States | 1,319 |
| United Kingdom | 791 |
| Germany | 666 |
| Spain | 613 |
| Canada | 551 |
| Japan | 531 |
| France | 496 |
| Italy | 476 |
| South Korea | 469 |
| Poland | 453 |
| China | 447 |
| Sweden | 342 |
| Australia | 341 |
| Taiwan | 334 |
| Hungary | 331 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Ad… |
| 2026-10-20 | New trial posted | ROSY-S: Rollover Study for Participants Who have Completed a Previous Study with Anifrolu… |
| 2026-10-20 | New trial posted | A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma |
| 2026-10-20 | New trial posted | GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-develope… |
| 2026-10-16 | New trial posted | A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Dur… |
| 2026-10-15 | New trial posted | A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerabil… |
| 2026-10-06 | New trial posted | A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment… |
| 2026-10-01 | New trial posted | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombinat… |
| 2026-09-23 | New trial posted | A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab De… |
| 2026-09-17 | New trial posted | Study of Safety and PK of AZD0543 in Healthy Adults |
| 2026-09-14 | New trial posted | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-se… |
| 2026-09-10 | New trial posted | A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion o… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06120491 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physicia… | Phase 3 | Not yet recruiting | Austria, Australia, Belgium, Brazil +21 |
| NCT06087835 | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Bulgaria +25 |
| NCT05057494 | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic… | Phase 3 | Active, not recruiting | Australia, Czechia, Spain, France +3 |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Pa… | Phase 3 | Recruiting | Austria, Australia, Brazil, Canada +19 |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +20 |
| NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum B… | Phase 3 | Active, not recruiting | Australia, Brazil, Canada, China +11 |
| NCT05702229 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophage… | Phase 2 | Recruiting | China, Spain, United Kingdom, Japan +3 |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | Phase 1/2 | Active, not recruiting | Australia, Belgium, Brazil, China +12 |
| NCT04157348 | Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. | Phase 3 | Active, not recruiting | Belgium, Canada, Germany, France +5 |
| NCT03813407 | An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia | Phase 3 | Recruiting | Brazil, Canada, China, Germany +9 |
| NCT05303532 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab | Phase 3 | Recruiting | Argentina, Australia, Belgium, Bulgaria +26 |
| NCT04550260 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | Phase 3 | Active, not recruiting | Belgium, Brazil, Canada, China +11 |
| 2023-506757-38-00 | PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Coopera… | Phase 1 | Not yet recruiting | Spain, France, Netherlands |
| NCT05301842 | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC | Phase 3 | Active, not recruiting | Belgium, Brazil, Canada, China +18 |
| NCT03616587 | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. | Phase 1 | Active, not recruiting | Spain, United Kingdom, United States |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | Phase 1/2 | Recruiting | Australia, Brazil, Canada, China +9 |
| NCT04877691 | Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus | Phase 3 | Active, not recruiting | Argentina, Bulgaria, Chile, Colombia +11 |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable o… | Phase 3 | Active, not recruiting | Argentina, Belgium, Brazil, Canada +18 |
| NCT05309668 | Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years… | Phase 1/2 | Active, not recruiting | Germany, Spain, Italy, Japan +3 |
| NCT05138133 | Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | Phase 3 | Active, not recruiting | Argentina, Belgium, Bulgaria, Brazil +19 |
| NCT04784714 | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and P… | Phase 3 | Active, not recruiting | Belgium, Germany, Denmark, Spain +5 |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Ma… | Phase 1/2 | Active, not recruiting | Australia, Canada, China, Czechia +10 |
| NCT04351555 | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Pati… | Phase 3 | Active, not recruiting | Austria, Bulgaria, Brazil, Canada +20 |
| NCT06268873 | A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on C… | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Bulgaria +33 |
| NCT05629585 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage… | Phase 3 | Active, not recruiting | Belgium, Brazil, Canada, China +13 |
Hiring for clinical development
AstraZeneca AB has 127 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites.
Website: astrazeneca.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "AstraZeneca AB clinical trials: 525 open, 830 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/astrazeneca-com/, data as of 2026-10-25.